An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures
An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures
The purpose of this study is to obtain long-term safety and tolerability information on
 carisbamate as add-on therapy for the treatment of partial onset seizures in patients with
 epilepsy. Seizure counts will be obtained to measure the rate of seizures for each patient
 during the study.
CARISEPY3014 is the open-label extension study that follows the double-blind study
 CARISEPY3013 (NCT00740623). In an open label study such as CARISEPY3014, both the physician
 and the patient know the name of the assigned study medication. In a double blind study such
 as CARISEPY-3013, neither the physician nor the patient knows the name of the assigned study
 medication. Patients who complete the 14-week double-blind treatment phase of study
 CARISEPY3013 will be eligible to enter the open-label extension study during which patients
 will transition through a 1-week blinded period to open-label carisbamate. There will be a 1
 week blinded transition during which patients will take blinded study medication; after this,
 patients will then take unblinded, open-label study medication. Safety assessments include
 the monitoring of the frequency, severity, and timing of adverse events, clinical laboratory
 test results, 12-lead electrocardiogram (ECG) recordings, vital signs measurements, physical
 and neurologic examinations, the Physician Withdrawal Checklist for symptoms of withdrawal
 for those patients who taper and/or discontinue study drug, and pregnancy tests for females
 of childbearing potential. Seizure counts will be obtained at every visit. The Quality of
 Life in Epilepsy-31 Patient Inventory questionnaire will be administered once during the
 study. A Medical Resource utilization questionnaire will be used to obtain cost-effectiveness
 information on carisbamate and will be administered twice during the study. There is no
 statistical testing hypothesis for this study. Carisbamate tablets taken twice daily in 2
 equally divided doses, with or without food, and taken with noncarbonated water. During the
 first week on study, patients will take blinded transition study medication and thereafter
 will take a target dosage of 800 mg/day of unblinded, open-label study medication. The dosage
 of study medication will range from 400 to 1,200 mg/day. Patients will receive treatment for
 1 year with the potential to receive treatment longer.
Inclusion Criteria:

 -  Must have completed the 14-week double-blind treatment phase of study CARISEPY3013

 -  must be willing/able to follow the restrictions and prohibitions of the protocol

 -  must be able to complete the patient diaries correctly (patients or legally acceptable
 representatives)

 -  must sign an informed consent form indicating agreement to participate in the study
 (patients or legally acceptable representatives)

 -  adolescents capable of understanding the nature of the study must provide assent to
 participate in the study

 Exclusion Criteria:

 -  Patients who have not completed the 14-week double-blind treatment phase of study
 CARISEPY3013.